Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study(WJOG9416L)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000030598
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Not provided
1) Active multiple cancer 2) Active infection 3) Interstitial pneumonia/pulmonary fibrosis 4) Uncontrolled diabetes 5) Uncontrolled hypertension 6) Clinically significant heart failure or uncontrolled arythmia 7) Ileus, inflammatory bowel disease, or chronic diarrhea 8) Uncontrolled thromboembolism 9) HIV associated disease 10) Severe psychological disease 11) Severe liver dysfunction such as cirrhosis 12) Prescription of steroids and/or immunosuppressant 13) Anticoaglation with warfarin or heparin 14) Prescription of long-term NSAIDS or antiplatelets 15) Fever >= 38.0 degrees C 16) Recent history of hemoptysis 17) Recent history of cardio-brain vascular disease 18) Incurable wound, ulcer, or bone fracture 19) Recent history of bleeding, vasculitis, or gastrointestinal hemorrhage 20) Recent history of gastrointestinal perforation/fistula 21) History of hypersensitivity by agents containing polysorbate 80 22) Plan of major surgery during the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method